Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications

Purpose: To determine the prevalence of ocular surface disease (OSD) in patients with glaucoma using topical intraocular pressure (IOP)-lowering therapy. Methods: This prospective observational study enrolled patients with primary open-angle glaucoma or ocular hypertension who were on a topical IOP-lowering medication regimen. Enrolled patients completed the ocular surface disease index (OSDI) and OSDI scores (0-100, with 0 representing no symptoms) were calculated for each patient. Medical history, demographics, and concomitant medication information were also collected. Results: Overall, 630 patients from 10 sites participated. Of these, 305 patients (48.4%) had an OSDI score indicating either mild (n = 134, 21.3%), moderate (n = 84, 13.3%), or severe (n = 87, 13.8%) OSD symptoms. OSDI scores were significantly different between patients with and without a prior diagnosis of dry eye syndrome (25.2 ± 15.4 vs 15.4 ± 15.8, respectively; P = 0.0036) and between patients who did and did not use artificial tears at the time of study participation (23.0 ± 15.6 vs 15.3 ± 15.8, respectively; P = 0.0046). Mean OSDI scores varied significantly with the number of topical IOP-lowering medications used, with higher (more severe) OSDI scores in patients using multiple IOP-lowering medications. Specifically, patients on a single medication had a mean OSDI score of 12.9 ± 13.1, which was significantly lower than those of patients on 2 (16.7 ± 17.0; P = 0.007) or 3 medications (19.4 ± 18.1; P = 0.0001). Conclusions: OSD is prevalent among medically treated patients with glaucoma. The severity of OSD symptoms is positively correlated to the number of IOP-lowering medications used.

[1]  E. Holland,et al.  Incidence and Prevalence of Glaucoma in Severe Ocular Surface Disease , 2006, Cornea.

[2]  G. Ousler,et al.  Evaluation of the comfort of Alphagan® P compared with Alphagan® in irritated eyes , 2003, Advances in therapy.

[3]  R. Gurny,et al.  Ocular tolerance of preservatives and alternatives. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  M. C. Leske,et al.  Prevalence of open-angle glaucoma among adults in the United States. , 2004, Archives of ophthalmology.

[5]  B. Reis,et al.  Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. , 2000, Ophthalmology.

[6]  Robert N Weinreb,et al.  Prevalence of Ocular Surface Disease in Glaucoma Patients , 2008, Journal of glaucoma.

[7]  C. Baudouin,et al.  Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication , 2002, The British journal of ophthalmology.

[8]  S. Kinoshita,et al.  Comparison of the Short-Term Effects on the Human Corneal Surface of Topical Timolol Maleate With and Without Benzalkonium Chloride , 2003, Journal of glaucoma.

[9]  R. Schiffman,et al.  Reliability and validity of the Ocular Surface Disease Index. , 2000, Archives of ophthalmology.

[10]  R. Klein,et al.  Prevalence of and risk factors for dry eye syndrome. , 2000, Archives of ophthalmology.

[11]  Robert W. Massof,et al.  Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study. , 2004, Archives of ophthalmology.

[12]  B. Munoz,et al.  Prevalence of dry eye among the elderly. , 1997, American journal of ophthalmology.

[13]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1 , 2000 .

[14]  M. C. Acosta,et al.  Decreased corneal sensitivity in patients with dry eye. , 2005, Investigative ophthalmology & visual science.

[15]  B. Reis,et al.  Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial☆ , 2000 .

[16]  C. Baudouin Side effects of antiglaucomatous drugs on the ocular surface. , 1996, Current opinion in ophthalmology.

[17]  J. Pichert,et al.  Compliance Barriers in Glaucoma: A Systematic Classification , 2003, Journal of glaucoma.

[18]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. , 2000, Ophthalmology.